Pacira Pharma (PCRX): EXPAREL Sales Are Tracking Below Consensus - Wedbush

September 21, 2016 8:16 AM EDT
Get Alerts PCRX Hot Sheet
Price: $36.55 --0%

Rating Summary:
    11 Buy, 3 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 1 | Down: 2 | New: 2
Trade PCRX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Pacira Pharmaceuticals (NASDAQ: PCRX) while noting that the Symphony Health EXPAREL estimated sales per day in August decreased -12% over July and total August sales tracked about -13.6% below consensus. Symphony Health sales and volume estimates for August were more than $21 million and 66-67 thousand pack units.

Combining July and August estimates, EXPAREL appears to be tracking about -7.6% below consensus. The September SH sales estimate is expected to be released on October 19.

No change to the price target of $109.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $40.37 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Liana Moussatos

Add Your Comment